- JP-listed companies
- Fuso Pharmaceutical Industries,Ltd.
Fuso Pharmaceutical Industries,Ltd.JP:4538
Market cap
¥20.8B
P/E ratio
15.1x
| Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | |
| Profit (loss) before income taxes | 2,649 | 652 | 117 | 1,061 | 1,361 | 1,255 | 1,042 | 2,345 | 1,911 | 2,205 | 1,767 |
| Depreciation | 1,878 | 1,914 | 1,513 | 2,004 | 1,921 | 1,967 | 2,381 | 2,410 | 2,559 | 2,486 | 2,263 |
| Loss (gain) on sale of investment securities | - | - | -25 | - | -36 | - | -22 | -38 | - | -138 | -39 |
| Loss on retirement of non-current assets | 92 | 26 | 55 | 16 | 38 | 19 | 20 | 11 | 15 | 10 | 20 |
| Loss on valuation of investment securities | - | - | - | - | - | - | 42 | - | 69 | - | 119 |
| Increase (decrease) in provision for bonuses | 14 | -24 | -65 | 48 | -19 | -19 | -11 | 60 | -20 | 20 | -8 |
| Increase (decrease) in provision for retirement benefits | 84 | 34 | -28 | 7 | -54 | -153 | -132 | -122 | -45 | -30 | -142 |
| Interest and dividend income | -61 | -86 | -85 | -100 | -86 | -92 | -87 | -79 | -82 | -89 | -96 |
| Interest expenses | 239 | 222 | 226 | 222 | 220 | 226 | 224 | 196 | 176 | 165 | 171 |
| Decrease (increase) in trade receivables | 1,650 | -216 | 549 | -725 | -620 | -84 | 1,661 | -983 | 231 | -588 | -2,587 |
| Decrease (increase) in inventories | -511 | -529 | 284 | -731 | 96 | -654 | 280 | -712 | 213 | -1,940 | -1,751 |
| Increase (decrease) in trade payables | -225 | 398 | -536 | 501 | -529 | 416 | 634 | -325 | 715 | 1,452 | 1,746 |
| Other, net | -142 | 33 | -27 | 310 | 438 | -305 | 285 | 268 | -1,106 | -383 | -183 |
| Subtotal | 5,547 | 2,396 | 1,942 | 2,101 | 2,136 | 2,536 | 6,241 | 3,537 | 4,572 | 3,169 | 1,280 |
| Interest and dividends received | 57 | 85 | 85 | 100 | 86 | 92 | 94 | 79 | 82 | 89 | 96 |
| Interest paid | -248 | -222 | -225 | -225 | -217 | -229 | -234 | -195 | -176 | -166 | -170 |
| Income taxes paid | -2,467 | -316 | - | -99 | -584 | -348 | -374 | -190 | -979 | -239 | -578 |
| Net cash provided by (used in) operating activities | 2,889 | 1,943 | 2,117 | 1,876 | 1,420 | 2,051 | 5,726 | 3,230 | 3,498 | 2,853 | 627 |
| Purchase of property, plant and equipment | -1,655 | -2,538 | -5,312 | -1,838 | -961 | -2,296 | -2,492 | -1,182 | -1,408 | -1,546 | -3,245 |
| Purchase of intangible assets | - | - | - | -318 | -756 | -22 | -10 | -28 | -79 | -28 | -343 |
| Proceeds from sale of investment securities | - | - | 32 | 2 | 73 | - | 74 | 40 | - | 242 | 84 |
| Other, net | -237 | -215 | -137 | -81 | -166 | -74 | -141 | 17 | -125 | -40 | -32 |
| Net cash provided by (used in) investing activities | -1,779 | -2,890 | -5,336 | -786 | -984 | -2,369 | -1,485 | -978 | -1,553 | -1,373 | -3,536 |
| Proceeds from long-term borrowings | 1,890 | 3,150 | 6,700 | 3,500 | 4,600 | 4,900 | 3,250 | 2,400 | 2,890 | 3,536 | 4,900 |
| Repayments of long-term borrowings | -3,528 | -3,193 | -3,214 | -3,465 | -3,456 | -3,871 | -4,370 | -4,314 | -4,032 | -3,819 | -3,587 |
| Purchase of treasury shares | -14 | -10 | -7 | -282 | -427 | -6 | -2 | -4 | -2 | -3 | -652 |
| Dividends paid | -812 | -722 | -721 | -717 | -706 | -700 | -613 | -525 | -525 | -525 | -645 |
| Other, net | - | - | - | - | - | -13 | - | - | - | - | - |
| Net cash provided by (used in) financing activities | -2,425 | -955 | 2,326 | -1,145 | 69 | -313 | -1,799 | -2,446 | -1,671 | -813 | 14 |
| Net increase (decrease) in cash and cash equivalents | -1,315 | -1,902 | -892 | -55 | 506 | -630 | 2,442 | -194 | 273 | 667 | -2,894 |